Mavrilimumab(抗GM-CSF受体α单抗)治疗类风湿关节炎的随机IIb期研究
这项随机IIb期研究纳入326例对至少一种合成DMARDs应答不足的中重度RA患者,在MTX基础上加用皮下mavrilimumab(150/100/30 mg)或安慰剂每两周一次治疗24周。结果显示各剂量组DAS28-CRP改善和ACR20应答率均显著优于安慰剂,未发现治疗相关安全信号。
要点
- mavrilimumab各剂量组DAS28-CRP较基线的改善均显著优于安慰剂(p<0.001)。
- 第24周ACR20应答率:150 mg组73.4%、100 mg组61.2%、30 mg组50.6%,安慰剂组24.7%(p<0.001)。
- 不良事件发生率各组与安慰剂相近,未发现治疗相关安全信号。
核心结论
- mavrilimumab可显著降低RA疾病活动度,起效早且具有临床意义的应答,代表一种新的作用机制并具有治疗潜力。
研究设计与样本
- 随机、双盲、安慰剂对照IIb期研究(NCT01706926),2012年9月至2013年6月进行。
- 纳入对至少一种合成DMARDs应答不足、DAS28-CRP/ESR≥3.2、尽管使用MTX仍有≥4个肿胀关节的中重度RA患者。
- 326例患者按1:1:1:1随机接受皮下mavrilimumab 150 mg(n=79)、100 mg(n=85)、30 mg(n=81)或安慰剂(n=81)每两周一次,联合MTX治疗24周,305例完成研究。
主要发现
- DAS28-CRP自基线至第12周变化(均值±SE):150 mg组-1.90(0.14)、100 mg组-1.64(0.13)、30 mg组-1.37(0.14)、安慰剂组-0.68(0.14),各剂量组与安慰剂比较p<0.001。
- 第24周ACR20应答率:150 mg组73.4%、100 mg组61.2%、30 mg组50.6%、安慰剂组24.7%(p<0.001)。
- 不良事件报告例数:150 mg组43例(54.4%)、100 mg组36例(42.4%)、30 mg组41例(50.6%)、安慰剂组38例(46.9%)。
- 未发现治疗相关安全信号。
关键数值与推荐
- 共同主要终点为第12周DAS28-CRP自基线变化和第24周ACR20应答率。
- ACR20应答率各mavrilimumab剂量组与安慰剂比较p<0.001。
临床怎么用
- 对于MTX应答不足的中重度RA患者,mavrilimumab每两周皮下注射联合MTX可显著改善疾病活动度并提高ACR20应答率。
- 该药代表靶向GM-CSF受体α的新机制,可作为传统DMARDs或生物制剂应答不足患者的潜在选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA. METHODS: In a phase IIb study (NCT01706926), patients with inadequate response to ≥1 synthetic disease-modifying antirheumatic drug(s), Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate ≥3.2, ≥4 swollen joints despite methotrexate (MTX) were randomised 1:1:1:1 to subcutaneous mavrilimumab (150, 100, 30 mg), or placebo every other week (eow), plus MTX for 24 weeks. Coprimary outcomes were DAS28-CRP change from baseline to week 12 and American College of Rheumatology (ACR) 20 response rate (week 24). RESULTS: 326 patients were randomised (150 mg, n=79; 100 mg, n=85; 30 mg, n=81; placebo, n=81); 305 completed the study (September 2012-June 2013). Mavrilimumab treatment significantly reduced DAS28-CRP scores from baseline compared with placebo (change from baseline (SE); 150 mg: -1.90 (0.14), 100 mg: -1.64 (0.13), 30 mg: -1.37 (0.14), placebo: -0.68 (0.14); p<0.001; all dosages compared with placebo).Significantly more mavrilimumab-treated patients achieved ACR20 compared with placebo (week 24: 73.4%, 61.2%, 50.6% vs 24.7%, respectively (p<0.001)). Adverse events were reported in 43 (54.4%), 36 (42.4%), 41 (50.6%) and 38 (46.9%) patients in the mavrilimumab 150, 100, 30 mg eow and placebo groups, respectively. No treatment-related safety signals were identified. CONCLUSIONS: Mavrilimumab significantly decreased RA disease activity, with clinically meaningful responses observed 1 week after treatment initiation, representing a novel mechanism of action with persuasive therapeutic potential. TRIAL REGISTRATION NUMBER: NCT01706926; results.
引用
- Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28213566. doi:10.1136/annrheumdis-2016-210624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。